問卷

TPIDB > Search Result

Search Result

篩選

List

1621Cases

2025-05-01 - 2030-04-30

Phase III

Active
A global, multicenter, randomized, open-label phase 3 trial comparing sacituzumab govitecan with standard of care (SOC) in previously treated extensive-stage small cell lung cancer (ES-SCLC) participants.
  • Condition/Disease

    ORR is defined as the percentage of participants who achieve a complete response (CR) or a partial response (PR) as assessed by BICR according to RECIST v1.1. OS is defined as the length of time elapsed from random assignment until the date of death from any cause.

  • Test Drug

    TRODELVY for Injection

Participate Sites
9Sites

Recruiting9Sites

2015-04-01 - 2020-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
20Sites

Terminated19Sites

2019-12-01 - 2030-05-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Not yet recruiting4Sites

Recruiting12Sites

2020-11-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting3Sites

2021-06-01 - 2031-12-24

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2020-12-01 - 2025-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-06-01 - 2032-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-04-01 - 2030-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2025-02-01 - 2032-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-09-01 - 2033-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting2Sites

Terminated2Sites